Business Context and Reporting Period
Company: Milestone Scientific Inc. (MLSS)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2025
Business Overview: Milestone Scientific designs and commercializes computer-controlled anesthetic delivery devices for dental (CompuDent, STA) and medical (CompuFlo) markets. The company operates as a smaller reporting company and relies on third-party manufacturers for production.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Product Sales (Net) | $2,232,420 | $2,248,845 |
| Gross Profit | $1,647,435 | $1,676,103 |
| Gross Margin | 73.8% | 74.5% |
| Net Loss | $(1,994,586) | $(1,440,529) |
| Loss Per Share (Basic/Diluted) | $(0.02) | $(0.02) |
| Cash and Cash Equivalents | $2,246,387 | $4,005,477 |
| Working Capital | $4,181,293 | $5,542,427 |
| Net Cash Used in Operating Activities | $(1,008,089) | $(1,218,128) |
Material Changes vs. Prior Period
- Revenue: Net product sales decreased slightly by $16,425 (0.7%) compared to Q1 2024. Dental revenue declined by $60,255, while Medical revenue increased by $43,830.
- Expenses: Total operating expenses increased by $504,117 to $3.65 million. This was driven primarily by a $274,909 increase in Research and Development (R&D) expenses related to the next-generation STA instrument, and a $221,452 increase in Selling, General, and Administrative (SG&A) expenses due to higher professional fees and warehousing costs.
- Profitability: The operating loss widened by $532,785 to approximately $2.0 million. The Dental segment operating income decreased significantly from $625,510 to $179,354, while the Medical segment loss narrowed slightly.
- Liquidity: Cash and cash equivalents decreased by approximately $1.01 million during the quarter. Inventory levels increased by $446,281.
Outlook, Risks, and Management Commentary
- Going Concern: The filing states that the company's history of operating losses and cash burn raises substantial doubt about its ability to continue as a going concern. Management plans to fund operations for the next 12 months using existing cash ($2.2 million) and a $800,000 related-party note financing received in April 2025.
- Strategic Shifts: Management has decided to delay all R&D on the next-generation Single Tooth Anesthesia System to conserve cash. The company is focusing on increasing revenue from dental and medical disposables and reducing professional fees.
- Financing: On April 9, 2025, the company issued $800,000 in promissory notes to three directors. These notes are convertible into common stock and bear interest at the prime rate less 2.50%.
- Risks: Key risks include reliance on two third-party manufacturers, potential supply chain disruptions (specifically chips and components), and exposure to U.S. tariff and trade policy changes affecting imports from China. The company also faces risks related to the commercialization of the CompuFlo Epidural System.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $2.2 million cash balance plus the $800,000 note to cover the ~$1 million quarterly operating cash burn.
- Related Party Transactions: Review the terms of the $800,000 notes issued to directors and the significant related-party payables (approx. $1.07 million total).
- Inventory Valuation: Confirm the valuation of the $4.16 million inventory, noting the $1.1 million allowance for slow-moving medical finished goods.
- Revenue Concentration: Assess the impact of E-Commerce (50% of sales) and the top international distributor (13% of sales) on future revenue stability.
- R&D Delays: Evaluate the long-term competitive impact of delaying the next-generation STA instrument development.